Attovia Therapeutics logo
Attovia Therapeutics
ATTO | NASDAQ
Chart Builder DCF Calculator
$14.72
-$0.41 (-2.71%)
At close: Nov 16, 2026, 4:00 PM ET

Attovia Therapeutics Company Profile

Company profile explained

Company Profile

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.

Key Executives

Name Position
Tao Fu CEO, President & Director
Hangjun Zhan Chief Technology Officer
Steven Chan Chief Financial Officer
Bora Han VP & Head of Preclinical Development
Hubert C. Chen Chief Medical Officer
Petter Veiby Chief Scientific Officer
Zaneta Odrowaz Chief Business Officer, Treasurer & Secretary

Latest SEC Filings

Date Type Title
Oct 08, 2026 4/A [Amend] Filing
Oct 08, 2026 4/A [Amend] Filing
Oct 08, 2026 3/A [Amend] Filing
Oct 08, 2026 3/A [Amend] Filing
Sep 02, 2026 10-Q Quarterly Report
Sep 02, 2026 8-K Current Report
Aug 28, 2026 144 Filing
Aug 28, 2026 4/A [Amend] Filing
Aug 28, 2026 4/A [Amend] Filing
Aug 13, 2026 4 Filing
View All SEC Filings ➞
Attovia Therapeutics
Attovia Therapeutics logo
Country United States
IPO Date Aug 5, 2026
Industry Biotechnology
Sector Healthcare
Employees 44
CEO Tao Fu

Contact Details

1091 Industrial Rd, Ste 310 San Carlos, California 94070 United States

Stock Details

Ticker Symbol ATTO
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0002058707
CUSIP Number 04987L102
ISIN Number US04987L1026
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.